Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab + Chemotherapy in ES-SCLC with Asymptomatic Brain Metastases
NCT04610684Phase 2Terminated
- Start
- Jan 2021
- Primary completion
- Jul 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of atezolizumab in small cell lung cancer (SCLC), brain metastases. Started Jan 2021; status: terminated.
02
Drugs
atezolizumab
03
Conditions
small cell lung cancer (SCLC)brain metastases
Beyond the preview
Go deeper on NCT04610684.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04610684.